PMID- 32852708
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 184
IP  - 2
DP  - 2020 Nov
TI  - Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the 
      prognosis of breast cancer patients.
PG  - 311-324
LID - 10.1007/s10549-020-05865-2 [doi]
AB  - PURPOSE: Various aberrations in the fibroblast growth factor receptor genes 
      FGFR1, FGFR2, and FGFR3 are found in different cancers, including breast cancer 
      (BC). This study analyzed the impact of FGFR amplification on the BC prognosis. 
      METHODS: The study included 894 BC patients. The amplification rates of FGFR1, 
      FGFR2, and FGFR3 were evaluated on tissue microarrays using fluorescence in situ 
      hybridization (FISH). Associations between these parameters and prognosis were 
      analyzed using multivariate Cox regression analyses. RESULTS: FGFR1 FISH was 
      assessable in 503 samples, FGFR2 FISH in 447, and FGFR3 FISH in 562. The FGFR1 
      amplification rate was 6.6% (n = 33). Increased FGFR2 copy numbers were seen in 
      0.9% (n = 4); only one patient had FGFR3 amplification (0.2%). Most patients with 
      FGFR1 amplification had luminal B-like tumors (69.7%, n = 23); only 32.6% 
      (n = 153) of patients without FGFR1 amplification had luminal B-like BC. Other 
      patient and tumor characteristics appeared similar between these two groups. 
      Observed outcome differences between BC patients with and without FGFR1 
      amplification did not achieve statistical significance; however, there was a 
      trend toward poorer distant metastasis-free survival in BC patients with FGFR1 
      amplification (HR = 2.08; 95% CI 0.98 to 4.39, P = 0.05). CONCLUSION: FGFR1 
      amplification occurs most frequently in patients with luminal B-like BC. The 
      study showed a nonsignificant correlation with the prognosis, probably due to the 
      small sample size. Further research is therefore needed to address the role of 
      FGFR1 amplifications in early BC patients. FGFR2 and FGFR3 amplifications are 
      rare in patients with primary BC.
FAU - Erber, Ramona
AU  - Erber R
AUID- ORCID: 0000-0003-0315-1229
AD  - Institute of Pathology, Comprehensive Cancer Center EMN, Erlangen University 
      Hospital, Friedrich Alexander University of Erlangen-Nuremberg (FAU), 
      Krankenhausstrasse 8-10, 91054, Erlangen, Germany. ramona.erber@uk-erlangen.de.
FAU - Rubner, Matthias
AU  - Rubner M
AD  - Department of Obstetrics and Gynecology, Comprehensive Cancer Center EMN, 
      Erlangen University Hospital, Friedrich Alexander University of 
      Erlangen-Nuremberg (FAU), Erlangen, Germany.
FAU - Davenport, Simon
AU  - Davenport S
AD  - Department of Pathology, Norris Comprehensive Cancer Center, University of 
      Southern California, Los Angeles, CA, USA.
FAU - Hauke, Sven
AU  - Hauke S
AD  - ZytoVision GmbH, Bremerhaven, Germany.
FAU - Beckmann, Matthias W
AU  - Beckmann MW
AD  - Department of Obstetrics and Gynecology, Comprehensive Cancer Center EMN, 
      Erlangen University Hospital, Friedrich Alexander University of 
      Erlangen-Nuremberg (FAU), Erlangen, Germany.
FAU - Hartmann, Arndt
AU  - Hartmann A
AD  - Institute of Pathology, Comprehensive Cancer Center EMN, Erlangen University 
      Hospital, Friedrich Alexander University of Erlangen-Nuremberg (FAU), 
      Krankenhausstrasse 8-10, 91054, Erlangen, Germany.
FAU - Haberle, Lothar
AU  - Haberle L
AD  - Department of Obstetrics and Gynecology, Comprehensive Cancer Center EMN, 
      Erlangen University Hospital, Friedrich Alexander University of 
      Erlangen-Nuremberg (FAU), Erlangen, Germany.
AD  - Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University 
      Hospital, Erlangen, Germany.
FAU - Gass, Paul
AU  - Gass P
AD  - Department of Obstetrics and Gynecology, Comprehensive Cancer Center EMN, 
      Erlangen University Hospital, Friedrich Alexander University of 
      Erlangen-Nuremberg (FAU), Erlangen, Germany.
FAU - Press, Michael F
AU  - Press MF
AD  - Department of Pathology, Norris Comprehensive Cancer Center, University of 
      Southern California, Los Angeles, CA, USA.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Department of Obstetrics and Gynecology, Comprehensive Cancer Center EMN, 
      Erlangen University Hospital, Friedrich Alexander University of 
      Erlangen-Nuremberg (FAU), Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
SB  - IM
MH  - *Breast Neoplasms/genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - *Receptor, Fibroblast Growth Factor, Type 1/genetics
MH  - Receptor, Fibroblast Growth Factor, Type 2/genetics
MH  - Receptors, Fibroblast Growth Factor/genetics/metabolism
PMC - PMC7599145
OTO - NOTNLM
OT  - Amplification
OT  - Breast cancer
OT  - FGFR1
OT  - FGFR2
OT  - FGFR3
OT  - FISH
OT  - Prognosis
COIS- P.A.F. has received honoraria from Roche, Pfizer, Novartis, and Celgene. His 
      institution conducts research for Novartis, Cepheid, and BioNTech. H.A. has 
      received honoraria from BMS, MSD, Roche, AstraZeneca, Boehringer Ingelheim, 
      Abbvie, Jansen-Cilag, and Ipsen. R.E. has received honoraria from Roche, Eisai, 
      Pfizer, and Novartis. The institution of H.A. and R.E. conducts research for 
      AstraZeneca, Roche, Janssen-Cilag, NanoString Technologies, Novartis, Cepheid, 
      and BioNTech. M.F.P. has received honoraria from Biocartis, Eli Lilly & Company, 
      Zymeworks, Novartis, and Puma Biotechnology. His institution conducts research 
      for Eli Lilly & Company, Zymeworks, Novartis, Cepheid, and Puma Biotechnology. 
      P.G. received honoraria from Novartis, financial support for symposia from 
      Novartis, Roche, and PharmaMar, and compensation for travel expenses from 
      discovering hands(R) company. S.H. is founder, shareholder, and managing director 
      of ZytoVision GmbH, Bremerhaven, Germany, the manufacturer of FISH probes used in 
      this study. The other authors have no conflicts of interest to declare.
EDAT- 2020/08/28 06:00
MHDA- 2021/06/24 06:00
PMCR- 2020/08/27
CRDT- 2020/08/28 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/27 00:00 [pmc-release]
AID - 10.1007/s10549-020-05865-2 [pii]
AID - 5865 [pii]
AID - 10.1007/s10549-020-05865-2 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2020 Nov;184(2):311-324. doi: 
      10.1007/s10549-020-05865-2. Epub 2020 Aug 27.